Ali Rizvi to Atherosclerosis
This is a "connection" page, showing publications Ali Rizvi has written about Atherosclerosis.
Connection Strength
2.549
-
Current and emerging drugs for the treatment of atherosclerosis: the evidence to date. Expert Rev Cardiovasc Ther. 2022 Jul; 20(7):515-527.
Score: 0.687
-
Incretin-based therapies, glucometabolic health and endovascular inflammation. Curr Pharm Des. 2014; 20(31):4953-60.
Score: 0.381
-
Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am J Med Sci. 2009 Oct; 338(4):310-8.
Score: 0.283
-
Inflammation markers as mediators of vasculo-endothelial dysfunction and atherosclerosis in the metabolic syndrome. Chin Med J (Engl). 2007 Nov 05; 120(21):1918-24.
Score: 0.248
-
The role of inflammation in diabetes and its complications. South Med J. 2006 Jan; 99(1):8-9.
Score: 0.219
-
Novel Therapeutical Approaches to Managing Atherosclerotic Risk. Int J Mol Sci. 2021 Apr 28; 22(9).
Score: 0.158
-
Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study. Diabetes Res Clin Pract. 2019 Mar; 149:163-169.
Score: 0.136
-
Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opin Biol Ther. 2015; 15(10):1391-7.
Score: 0.106
-
Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia? Curr Pharm Des. 2013; 19(21):3858-68.
Score: 0.089
-
The role of elevated growth hormone on the increased atherosclerosis in patients with acromegaly. Angiology. 2012 Oct; 63(7):492-4.
Score: 0.084
-
Hypertension, obesity, and inflammation: the complex designs of a deadly trio. Metab Syndr Relat Disord. 2010 Aug; 8(4):287-94.
Score: 0.075
-
The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance? Acta Diabetol. 2009 Mar; 46(1):1-11.
Score: 0.066
-
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs. 2009 Oct; 18(10):1495-503.
Score: 0.018